
                                SEQUENCE LISTING

<110> Genmab A/S

<120> ANTI-TISSUE FACTOR ANTIBODY-DRUG
  CONJUGATES AND THEIR USE IN THE TREATMENT OF CANCER
  

<130> 76168-20009.40

<140> Not Yet Assigned    
<141> Concurrently Herewith            

<150> US 62/765,093       
<151> 2018-08-16  

<160> 16

<170> FastSEQ for Windows Version 4.0

<210> 1
<211> 8
<212> PRT
<213> Artificial Sequence

<220> 
<223> Synthetic Construct

<400> 1
Gly Phe Thr Phe Ser Asn Tyr Ala
 1               5              


<210> 2
<211> 8
<212> PRT
<213> Artificial Sequence

<220> 
<223> Synthetic Construct

<400> 2
Ile Ser Gly Ser Gly Asp Tyr Thr
 1               5              


<210> 3
<211> 11
<212> PRT
<213> Artificial Sequence

<220> 
<223> Synthetic Construct

<400> 3
Ala Arg Ser Pro Trp Gly Tyr Tyr Leu Asp Ser
 1               5                  10      


<210> 4
<211> 6
<212> PRT
<213> Artificial Sequence

<220> 
<223> Synthetic Construct

<400> 4
Gln Gly Ile Ser Ser Arg
 1               5      


<210> 5
<211> 3
<212> PRT
<213> Artificial Sequence

<220> 
<223> Synthetic Construct

<400> 5
Ala Ala Ser
 1          


<210> 6
<211> 9
<212> PRT
<213> Artificial Sequence

<220> 
<223> Synthetic Construct

<400> 6
Gln Gln Tyr Asn Ser Tyr Pro Tyr Thr
 1               5                  


<210> 7
<211> 118
<212> PRT
<213> Artificial Sequence

<220> 
<223> Synthetic Construct

<400> 7
Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
 1               5                  10                  15      
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asn Tyr
            20                  25                  30          
Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
        35                  40                  45              
Ser Ser Ile Ser Gly Ser Gly Asp Tyr Thr Tyr Tyr Thr Asp Ser Val
    50                  55                  60                  
Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
65                  70                  75                  80  
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
                85                  90                  95      
Ala Arg Ser Pro Trp Gly Tyr Tyr Leu Asp Ser Trp Gly Gln Gly Thr
            100                 105                 110         
Leu Val Thr Val Ser Ser
        115             


<210> 8
<211> 107
<212> PRT
<213> Artificial Sequence

<220> 
<223> Synthetic Construct

<400> 8
Asp Ile Gln Met Thr Gln Ser Pro Pro Ser Leu Ser Ala Ser Ala Gly
 1               5                  10                  15      
Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Ser Ser Arg
            20                  25                  30          
Leu Ala Trp Tyr Gln Gln Lys Pro Glu Lys Ala Pro Lys Ser Leu Ile
        35                  40                  45              
Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly
    50                  55                  60                  
Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
65                  70                  75                  80  
Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Tyr Asn Ser Tyr Pro Tyr
                85                  90                  95      
Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys
            100                 105         


<210> 9
<211> 25
<212> PRT
<213> Artificial Sequence

<220> 
<223> Synthetic Construct

<400> 9
Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
 1               5                  10                  15      
Ser Leu Arg Leu Ser Cys Ala Ala Ser
            20                  25  


<210> 10
<211> 17
<212> PRT
<213> Artificial Sequence

<220> 
<223> Synthetic Construct

<400> 10
Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser
 1               5                  10                  15      
Ser
    


<210> 11
<211> 38
<212> PRT
<213> Artificial Sequence

<220> 
<223> Synthetic Construct

<400> 11
Tyr Tyr Thr Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn
 1               5                  10                  15      
Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp
            20                  25                  30          
Thr Ala Val Tyr Tyr Cys
        35              


<210> 12
<211> 11
<212> PRT
<213> Artificial Sequence

<220> 
<223> Synthetic Construct

<400> 12
Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser
 1               5                  10      


<210> 13
<211> 26
<212> PRT
<213> Artificial Sequence

<220> 
<223> Synthetic Construct

<400> 13
Asp Ile Gln Met Thr Gln Ser Pro Pro Ser Leu Ser Ala Ser Ala Gly
 1               5                  10                  15      
Asp Arg Val Thr Ile Thr Cys Arg Ala Ser
            20                  25      


<210> 14
<211> 17
<212> PRT
<213> Artificial Sequence

<220> 
<223> Synthetic Construct

<400> 14
Leu Ala Trp Tyr Gln Gln Lys Pro Glu Lys Ala Pro Lys Ser Leu Ile
 1               5                  10                  15      
Tyr
    


<210> 15
<211> 36
<212> PRT
<213> Artificial Sequence

<220> 
<223> Synthetic Construct

<400> 15
Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly
 1               5                  10                  15      
Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala
            20                  25                  30          
Thr Tyr Tyr Cys
        35      


<210> 16
<211> 10
<212> PRT
<213> Artificial Sequence

<220> 
<223> Synthetic Construct

<400> 16
Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys
 1               5                  10  

